Axsome Therapeutics, Inc. (AXSM)

Compare

111.67

-4.96

(-4.25%)

At close: April 1 at 4:00:02 PM EDT

111.61

-0.06

(-0.05%)

Pre-Market: 4:27:25 AM EDT

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Investor's Business Daily 12 hours ago

AXSM
-4.25%
Why Shares of Axsome Therapeutics Slumped Today

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand name Sunosi) in major depressive disorder (MDD). It was a six-week proof-of-concept phase 3 trial for MDD "with and without severe excess daytime sleepiness (EDS)."

Motley Fool 15 hours ago

AXSM
-4.25%
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder (MDD) w

GlobeNewswire 21 hours ago

AXSM
-4.25%
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Investor's Business Daily 7 days ago

SUPN

AXSM
-4.25%
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039, primary endpoint, 150 mg solriamfetol) Statistically significant reduction in overall ADHD disease severity as measured by the CGI-S score compared to placebo (p=0.017, key secondary endpoint, 150 mg solriamfetol) Statistically significant rate of clinical response on the AISRS compared to placebo (p=0.024, 150 mg solriamfetol) Onset of action as

GlobeNewswire 7 days ago

AXSM
-4.25%
Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 12 days ago

BIIB

AXSM
-4.25%
Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against other best performing growth stocks in 2025. Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector. […]

Insider Monkey 18 days ago

AXSM
-4.25%
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.

Zacks 26 days ago

HKMPY

AXSM
-4.25%
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. (Hikma) resolving patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted

GlobeNewswire 27 days ago

AXSM
-4.25%
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting a supplemental NDA (sNDA) submission for AXS-05 in Alzheimer’s disease agitation.

GlobeNewswire 29 days ago

AXSM
-4.25%
Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be […]

Insider Monkey last month

AXSM
-4.25%
TEVA
Axsome Therapeutics to Participate in Upcoming Investor Conferences

TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferenceThe Company will present on Tuesday, March 4,

GlobeNewswire last month

AXSM
-4.25%
Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Axsome Therapeutics ( NASDAQ:AXSM ) Full Year 2024 Results Key Financial Results Revenue: US$385.7m (up 43% from FY...

Simply Wall St. last month

AXSM
-4.25%
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (most commonly used drugs for migraine) met its primary endpoint. Symbravo demonstrated statistically significantly greater migraine treatment response than oral CGRP inhibitors, as measured by the Migraine Treatment Optimization Questionnaire (mTOQ-4) (5.2 versus 2.8, p<0.001). Also Read: Ax

Benzinga last month

AXSM
-4.25%
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

SYMBRAVO demonstrated statistically significantly greater migraine treatment response compared to prior treatment with an oral CGRP inhibitor (p<0.001, mTOQ-4 total score, primary endpoint) 2-hour pain freedom for most attacks reported at least half the time by 47.9% of patients after SYMBRAVO versus 1.0% after oral CGRPs (p<0.001) 24-hour or greater sustained pain relief after a single dose reported by 47.9% of patients after SYMBRAVO versus 16.7% after oral CGRPs (p<0.001) Ability to quickly r

GlobeNewswire last month

AXSM
-4.25%
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against the other best performing pharma stocks so far in 2025. What’s Going on in the Pharma Sector? On February 20, Jared […]

Insider Monkey last month

AXSM
-4.25%
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

A handful of biotech stocks made an elite list despite being unprofitable. But many show robust sales growth and constructive charts.

Investor's Business Daily last month

BEIGF

ONC

ARGNF
Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against other best performing healthcare stocks so far in 2025. The Healthcare Sector and its Dynamics in the Stock Market Despite the […]

Insider Monkey last month

AXSM
-4.25%
Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

Axsome Therapeutics Inc (AXSM) reports significant revenue growth driven by Auvelity and Sunosi, while navigating increased R&D expenses and strategic market challenges.

GuruFocus.com last month

AXSM
-4.25%
Q4 2024 Axsome Therapeutics Inc Earnings Call

Q4 2024 Axsome Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

AXSM
-4.25%

Performance Overview

Return	AXSM	S&P 500 (^GSPC)
YTD	+31.98%	-4.23%
1-Year	+45.04%	+7.42%
3-Year	+154.32%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week

Why Shares of Axsome Therapeutics Slumped Today

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025

Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

Q4 2024 Axsome Therapeutics Inc Earnings Call

Performance Overview